Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Pediatr Diabetes. 2015 Jul 23;16(7):465–484. doi: 10.1111/pedi.12299

Figure 4.

Figure 4

Monoclonal antibody mAb287 delays diabetes and islet lymphocyte infiltration in NOD mice. (A) Groups of 4-wk-old female NOD mice were treated weekly with PBS (n = 18; black squares), 0.1 mg of mouse IgG1 (n = 18; blue diamonds), 0.1 mg of mAb287 (n = 15; green circles), or 0.5 mg of mAb287 (n = 18; red triangles), and followed up to 30 wk. The percentages of diabetes free mice are shown. (B–D) Groups of eight mice were treated weekly from age 4–11 wk with 0.5 mg of control IgG1 (red bars) or mAb287 (blue bars) at which time pancreatic islets were pooled in each group. (B) The average number of live CD4 T cells, CD8 T cells, and 220+ B cells per pancreas. (C) The percentages of CD4 T cells specifically binding the IAg7–R3:RE, IAg7-R3:RGE or IAg7-chromogranin A (ChgA) tetramers, or CD8 T cells specifically binding the Kd-IGRP tetramer. (D) Average number of islet-infiltrating tetramer-positive cells per pancreas were calculated from the data in B and C (179) (With permission from the Proceedings of the National Academy of Sciences).